OnabotulinumtoxinA as a Treatment for Hemiplegic Migraine

Overview

About this study

Hemiplegic migraine is a rare subtype of migraine with aura, with symptoms affecting vision, speech and language, hearing, and sensory and motor disturbances. Muscle weakness and hemiplegia are defining characteristics of hemiplegic migraines. Compared to patients with typical migraine with aura, patients with hemiplegic migraine tend to have more prolonged aura symptoms. In some cases, reversible unilateral weakness may last days to weeks. The primary objective of this project is to evaluate the response of hemiplegic migraine patients evaluated at Mayo Clinic to onabotulinumtoxinA treatments.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Patient evaluated at Mayo Clinic with available charts, records, and images for review.
  • All patient ages will be included.
  • Diagnosis of hemiplegic migraine.
  • Treatment with onabotulinumtoxinA (150 units given every 3 months).

Exclusion Criteria: 

  • Patient not meeting the aforementioned inclusion criteria.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Carrie Robertson, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20305353

Mayo Clinic Footer